Sign in

You're signed outSign in or to get full access.

NB

Nuvation Bio Inc. (NUVB)·Q3 2025 Earnings Summary

Executive Summary

  • Q3 marked Nuvation’s first full commercial quarter: total revenue $13.12M, including $7.72M net product revenue from IBTROZI; net loss $(55.8)M, $(0.16) per share, with cash and marketable securities of $549.0M as of 9/30/25 .
  • Results beat S&P Global consensus: revenue $13.12M vs $6.86M* and EPS $(0.16) vs $(0.17)*, driven by 204 new patient starts and rapid payer coverage scaling to >80% by quarter-end .
  • Launch quality: management emphasized new patient starts over channel stocking (now “no longer material”), gross-to-net ~20% (expected to tick up then stabilize), and commercial footprint “right-sized” at 47 OAMs .
  • Pipeline/regulatory catalysts: sNDA to update label with 50‑month median DOR being submitted “by the end of the week”; in Japan, reimbursement is expected in Q4, triggering a $25M milestone and royalties; EU partnership discussions are “very advanced” for Q4 .
  • Strategic narrative: management is “comfortable with the level of consensus” and cited annualized net revenue of >$55M based on Q3 patient starts alone, with multi‑year stacking potential from IBTROZI’s 50‑month median DOR .

Values with asterisk (*) are retrieved from S&P Global.

What Went Well and What Went Wrong

What Went Well

  • Strong commercial start: 204 new U.S. patients started IBTROZI in Q3 (first full quarter), equating to >15 weekly starts; management positioned this as the fastest ROS1 launch in history .
  • Clinical durability updated: pooled TRUST-I/II data now show 50‑month median DOR in TKI‑naïve ROS1+ NSCLC; sNDA label update planned imminently to reflect this .
  • Access momentum: payer coverage surpassed 80% of covered lives by quarter-end (up from 58% two months prior), enabling faster conversion from free trial to paid therapy .
  • Quote: “We are thrilled that 204 new patients have received IBTROZI during our first full quarter as a commercial-stage company” — David Hung, M.D., Founder & CEO .

What Went Wrong

  • Operating expense intensity remains high amid scale-up: SG&A $37.4M (vs $19.6M YoY), reflecting headcount and launch investments; R&D $28.8M as TRUST‑IV and pipeline progressed .
  • Continued operating losses: net loss $(55.8)M vs $(41.2)M YoY driven by higher SG&A for launch, though sequentially improved vs Q2’s $(59.0)M .
  • No revenue guidance yet; management reiterates comfort with consensus but refrains from explicit outlook, leaving near‑term model variability to patient adoption and gross‑to‑net evolution .

Financial Results

MetricQ3 2024Q2 2025Q3 2025
Total Revenues ($)$0.727M $4.833M $13.120M
Product Revenue, net ($)$0 $1.238M $7.723M
Collaboration & License Revenue ($)$0.727M $3.595M $5.397M
Cost of Revenue ($)$1.515M $2.576M $3.349M
Gross Profit (Deficit) ($)$(0.788)M $2.257M $9.771M
R&D Expense ($)$27.731M $27.362M $28.846M
SG&A Expense ($)$19.582M $38.484M $37.359M
Net Loss ($)$(41.210)M $(59.007)M $(55.792)M
Diluted EPS ($)$(0.15) $(0.17) $(0.16)

Balance Sheet Highlights

MetricQ2 2025Q3 2025
Cash, Cash Equivalents & Marketable Securities ($)$607.7M $549.0M

Revenue Breakdown (Q3 2025)

Revenue LineQ3 2025 ($)Notes
Net Product Revenue (U.S. IBTROZI)$7.723M First full quarter of commercialization
Collaboration & License$5.397M R&D services (+$3.8M), product supply (+$0.6M), royalties (+$0.3M); Japan milestone pending

KPIs

KPIQ2 2025Q3 2025
New patient starts (U.S.)70 as of 7/31/25 204 in Q3
Payer coverage—>80% covered lives; 58% two months prior
Sales territories with prescribing—98% of 47 territories
Gross-to-net—~20%; expected to increase slightly then stabilize
Channel stocking impactQ2 included initial stocking “No longer material” in Q3

Estimate Comparison (S&P Global)

MetricConsensus*ActualComment
Revenue (Q3 2025)$6.86M*$13.12M Beat on launch strength
EPS (Q3 2025)$(0.17)*$(0.16) Modest beat (OPEX scale-up contained)

Values with asterisk (*) are retrieved from S&P Global.

Guidance Changes

Metric/ItemPeriodPreviousCurrentChange
Net revenue guidance2025Not providedNot provided Maintained
Gross-to-netNear-termn/a~20% now; to rise slightly then stabilize New detail
sNDA (label update for 50‑mo DOR)Near-termn/aSubmit “by end of the week” New
Japan reimbursement milestoneQ4 2025“Expected by year-end” $25M milestone expected in Q4; royalties to begin Maintained/timing clarified
EU commercialization partnershipQ4 2025n/a“Very advanced” discussions; update in Q4 New
Field force sizeOngoingn/a47 OAMs; no increase planned New
Cash runwayMulti‑yearSufficient post‑financingSufficient through profitability Maintained

Earnings Call Themes & Trends

TopicQ1 2025Q2 2025Q3 2025Trend
Regulatory/LabelNDA under Priority Review; PDUFA 6/23/25 FDA approval 6/11; NCCN Preferred Agent sNDA for 50‑mo DOR to be filed imminently Strengthening
Product PerformancePre‑launch prep 70 starts by 7/31 204 starts in Q3; >15/week Accelerating
Market Access—Launch and distribution set-up >80% coverage; rapid conversion from free trial Improving
R&D ExecutionPlanning safusidenib pivotal path Pivotal design evolving G203 moving to Phase 3; first patient enrolled; TRUST‑IV adjuvant started Advancing
Ex‑U.S. ExpansionChina approval (partner) —Japan approval (Sept); reimbursement imminent; EU partner discussions advanced Expanding
Financial Framework—Initial product revenue; launch opex ramp Channel stocking not material; GTN ~20%; annualized net revenue >$55M based on Q3 starts Maturing launch metrics

Management Commentary

  • “We are thrilled that 204 new patients have received IBTROZI during our first full quarter as a commercial‑stage company.” — David Hung, M.D., Founder & CEO .
  • “The median DOR…has now increased to 50 months…These long‑term data appear to represent the greatest patient benefit to date in ROS1‑positive NSCLC.” — David Hung, M.D. .
  • “Stocking no longer makes up a material amount of our product revenue…growth is now purely driven by treating new patients.” — Philippe Sauvage, CFO .
  • “If we consider our new patient starts in the quarter, we are already at a level of annualized net revenue of more than $55 million.” — Philippe Sauvage, CFO .
  • “IBTROZI’s outstanding efficacy and safety profile…have led to the fastest ROS1 launch in history.” — Colleen Sjogren, CCO .

Q&A Highlights

  • Outlook: No formal revenue guidance, but management is “comfortable with the level of consensus”; reiterated annualized revenue math based on Q3 starts and multi‑year DOR stacking .
  • Gross‑to‑Net/Payer Mix: GTN ~20% this quarter; mix expected ~40% Medicare, <10% Medicaid, ~20% 340B; GTN to rise modestly then stabilize .
  • Label Update: sNDA to include 50‑month median DOR “by end of the week,” enabling renewed HCP engagement post‑approval .
  • Ex‑U.S.: Japan reimbursement expected in Q4 triggering $25M milestone and royalties; EU deal “very advanced,” potential Q4 update .
  • Commercial Infrastructure: Field force set at 47 OAMs with no expansion planned; focus turning to community account penetration .

Estimates Context

  • Q3 2025 results exceeded S&P Global consensus: revenue $13.12M vs $6.86M*, EPS $(0.16) vs $(0.17)*, supported by 204 new patient starts and >80% coverage .
  • Forward consensus implies accelerating revenue: Q4 2025 revenue $32.68M* and EPS $(0.106)*; management did not give guidance but indicated comfort with consensus and highlighted multi‑year stacking from long DOR .

Values with asterisk (*) are retrieved from S&P Global.

Key Takeaways for Investors

  • Launch quality over quantity: revenue beat and EPS in line-to-better reflect genuine patient adoption (not channel fill), with coverage in place to sustain growth .
  • Durability is the differentiator: 50‑month median DOR underpins prevalence build and multi‑year revenue stacking; label update should reinforce first‑line positioning .
  • Near‑term catalysts: sNDA submission and potential label update; Japan reimbursement and $25M milestone; EU partnership announcement; incremental royalty flows .
  • Operating leverage will follow scale: while SG&A remains elevated for launch, sequential net loss improved and GTN dynamics are clarifying .
  • Pipeline optionality: safusidenib moving into a Phase 3, registrational-intent maintenance study in high‑grade IDH1 glioma expands medium‑term value drivers .
  • Modeling note: with 204 Q3 starts implying >$55M annualized net revenue from those patients alone, consensus for 2026 (~$115M cited on call) appears achievable if adoption and stacking continue .
  • Trading implications: positive estimate revisions likely on demonstrated demand/coverage momentum; watch for label update, Japan milestone, and EU deal as stock catalysts in Q4–Q1.

Additional Relevant Press Releases (Q3 2025)

  • Enrolled first patient in global, randomized safusidenib study with Phase 3, registrational intent; FDA aligned on PFS as primary endpoint .
  • Initiated TRUST‑IV Phase 3 adjuvant IBTROZI study; Japan approval achieved; reimbursement expected by year‑end .

Values with asterisk (*) are retrieved from S&P Global. All other figures and statements are sourced from company filings, press releases, and the Q3 2025 earnings call as cited.